Oncotelic Initiates Clinical Trials Evaluating OT-101 against Pediatric Gliomas
08 nov. 2022 07h33 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or “We”), a developer of treatments for rare and orphan indications,...
Global Immuno-Oncology Diagnostics Market Research Report 2022-2026: Diagnostics Plays New Key Role in Therapeutic Development and Clinical Trials
08 juin 2022 03h53 HE
|
Research and Markets
Dublin, June 08, 2022 (GLOBE NEWSWIRE) -- The "Market Forecasts for Immuno-Oncology Diagnostics, Including Executive/Consultant Guides and Customized Forecasting/Analysis 2022 - 2026" report has...
Akoya Biosciences to Showcase New Data on PhenoCycler-Fusion at the AACR Annual Meeting 2022
06 avr. 2022 08h05 HE
|
Akoya Biosciences, Inc.
Company to present industry’s first 100-plex, whole slide dataset for deep spatial phenotyping of the tumor microenvironmentThe Company will also showcase its novel protein chemistry to accelerate...
Global Immuno-Oncology Diagnostics Market Research Report 2022: Explosion in Immuno-Oncology Therapies Creates an Exploding Diagnostic Market - Forecast to 2027
29 mars 2022 04h13 HE
|
Research and Markets
Dublin, March 29, 2022 (GLOBE NEWSWIRE) -- The "Market Forecasts for Immuno-Oncology Diagnostics with COVID-19 Impact and Updates" report has been added to ResearchAndMarkets.com's offering....
Proto Oncogene Protein C-MYC Inhibitors Industry 2021 Featuring Insights for 15+ Companies and Drugs, Including RRx-001 (EpicentRx) and WP1066 (Moleculin Biotech)
23 déc. 2021 05h28 HE
|
Research and Markets
Dublin, Dec. 23, 2021 (GLOBE NEWSWIRE) -- The "Proto Oncogene Protein C-MYC Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering. This report...
Akoya Biosciences Announces a Groundbreaking Collaboration with PathAI to Combine Spatial Biology with AI-Powered Tools to Facilitate Discovery of Novel Predictive Biomarkers
13 déc. 2021 08h05 HE
|
Akoya Biosciences, Inc.
MARLBOROUGH, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, and PathAI, a global leader in artificial intelligence (AI)-powered...
Curesponse Secures Additional USD 8 Million Funding for Its Breakthrough Precision Oncology Platform
15 nov. 2021 14h35 HE
|
Curesponse
REẖOVOT, Israel, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Curesponse (www.curesponse.com) has secured additional USD 8 million funding for its breakthrough precision oncology platform. Curesponse is a...
Global Market for Immuno-Oncology Diagnostics 2021: Diagnostics Play New Key Role in Therapeutic Development and Clinical Trials
01 nov. 2021 05h48 HE
|
Research and Markets
Dublin, Nov. 01, 2021 (GLOBE NEWSWIRE) -- The "Market Forecasts for Immuno-Oncology Diagnostics with COVID-19 Impact and Updates, 2022 - 2026" report has been added to ResearchAndMarkets.com's...
Akoya Biosciences Appoints Diagnostics Industry Pioneer Myla Lai-Goldman, MD, to its Board of Directors
22 sept. 2021 08h05 HE
|
Akoya Biosciences, Inc.
MARLBOROUGH, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the appointment of Myla Lai-Goldman, MD, a true...
PD-1 Resistant Head and Neck Cancer (HNC) Market Landscape Report 2021
31 août 2021 04h08 HE
|
Research and Markets
Dublin, Aug. 31, 2021 (GLOBE NEWSWIRE) -- The "PD-1 Resistant Head and Neck Cancer (HNC) - Market Insight, Epidemiology and Market Forecast 2030" report has been added to ResearchAndMarkets.com's...